CSF3R/CD114 mediates infection-dependent transition to severe asthma - 07/02/19
Doi : 10.1016/j.jaci.2018.10.001
Hao Wang, PhD a, ∗, Meaghan FitzPatrick, PhD b, c, ∗, Nicholas J. Wilson, PhD c, Desiree Anthony, PhD a, Patrick C. Reading, PhD d, e, Catherine Satzke, PhD e, f, g, Eileen M. Dunne, PhD f, g, Paul V. Licciardi, PhD f, g, Huei Jiunn Seow, BSc Hons a, Kristy Nichol, PhD h, i, Ian M. Adcock, PhD j, Kian Fan Chung, MD, DSc j, Gary P. Anderson, PhD b, Ross Vlahos, PhD a, b, Peter Wark, MD, PhD h, i, Steven Bozinovski, PhD a, b 
a School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
b Department of Pharmacology & Therapeutics, Lung Health Research Centre, The University of Melbourne, Parkville, Victoria, Australia
c CSL Limited, Parkville, Victoria, Australia
d WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia
e Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia
f Pneumococcal Research, Murdoch Children's Research Institute, Parkville, Victoria, Australia
g Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
h Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, Australia
i Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
j Airways Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| This study was supported by funding from the National Health and Medical Research Council of Australia (grant no. APP1067547) and the Australian Research Council (grant no. FT130100654). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2018
The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 143 - N° 2
P. 785 - febbraio 2019 Ritorno al numero
Articolo precedente
- EROS/CYBC1 mutations: Decreased NADPH oxidase function and chronic granulomatous disease
- David C. Thomas, Louis-Marie Charbonnier, Andrea Schejtman, Hasan Aldhekri, Eve L. Coomber, Elizabeth R. Dufficy, Anne E. Beenken, James C. Lee, Simon Clare, Anneliese O. Speak, Adrian J. Thrasher, Giorgia Santilli, Hamoud Al-Mousa, Fowzan S. Alkuraya, Talal A. Chatila, Kenneth G.C. Smith
- Real-life treatment of cholinergic urticaria with omalizumab
- Sabine Altrichter, Mati Chuamanochan, Henriette Knoth, Aida Asady, Tatevik Ohanyan, Martin Metz, Marcus Maurer
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?